Abstract
Objective To investigate the relationship between the expression of CC chemokine ligand 5(CCL5) and S100 calcium binding protein A4 (S100A4) protein in breast cancer tissues with clinicopathological features and prognosis. Methods The expression of CCL5 and S100A4 in 40 cases of normal breast tissues and 120 cases of breast cancer were detected by immunohistochemistry, and the relationship between the degree of expression and the clinicopathological features and prognosis of breast cancer was analyzed. Results The expression positive rates of CCL5 and S100A4 in breast cancer tissues were 56.67% and 62.50% respectively, which were not expressed in normal breast tissues, and the differences were statistically significant(χCCL52=39.403, P 0.05). And the expression of S100A4 was statistically correlated with clinical staging(χ2=44.311, P 0.05). The expression of CCL5 and S100A4 in breast cancer was positively correlated(r=0.301, P<0.01). CCL5 was positively correlated with the recurrence of breast cancer(OR=6.270, P<0.01), and S100A4 was not correlated with the recurrence of breast cancer(OR=1.103, P=0.768). Survival analysis showed that the disease-free survival time of patients with positive CCL5 expression was significantly shorter than the patients with negative CCL5 expression(χ2=11.851, P<0.01), and the disease-free survival time of patients with positive S100A4 expression was significantly shorter than the patients with negative S100A4 expression(χ2=5.433, P=0.021). The joint detection showed that the disease-free survival time in CCL5(+ )+ S100A4(+ ) group was significantly lower than that of CCL5(+ ) or S100A4(+ ) group(χ2=15.341, P<0.01) and CCL5(-)+ S100A4(-)group(χ2=15.341, P<0.01). Conclusion The expression of CCL5 and S100A4 in breast cancer can reflect the metastasis and staging of breast cancer, which can be used to judge the clinical pathological characteristics and prognosis of breast cancer. Key words: Breast neoplasms; Chemokine CCL5; Calcium-binding proteins; Immunohistochemistry
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.